SUBSCRIBE
SUBSCRIBE

Kite Pharma

NEWS
Deals
Tiny Bob Langer-Backed Kite Pharma Files For $86 Million IPO
June 27, 2017
 · 
1 min read
Kite Pharma's CAR-T Blood Cancer Candidate Succeeds in Major Study
Drug Development
Kite Pharma Stock Plunges After Report of Patient Death in CAR-T Clinical Trial
May 8, 2017
 · 
2 min read
Novartis Unloads Former New York Space for $18 Million, Resold for $30 Million
Policy
Novartis AG Looks Over Its Shoulder as Kite Pharma Hits Its BLA Filing Deadline
April 3, 2017
 · 
2 min read
Kite Pharma's CAR-T Blood Cancer Candidate Succeeds in Major Study
Drug Development
Kite Pharma’s CAR-T Blood Cancer Candidate Succeeds in Major Study
February 28, 2017
 · 
3 min read
Policy
JPM17: Kite Pharma’s Strategy for Commercializing Its Lead CAR-T Drug
January 12, 2017
 · 
1 min read
Kite Pharma's CAR-T Blood Cancer Candidate Succeeds in Major Study
Business
On a Roll: Kite Pharma Bags $250 Million CAR-T Deal From Daiichi Sankyo, Inc., Forms Joint Venture With Fosun Pharma
January 9, 2017
 · 
3 min read
Kite Pharma's CAR-T Blood Cancer Candidate Succeeds in Major Study
Business
As Rival Juno Falters, Kite Pharma Touts New CAR-T Data and Maps Out BLA Submission Plans
December 5, 2016
 · 
2 min read
Kite Pharma's CAR-T Blood Cancer Candidate Succeeds in Major Study
Biotech Beach
With No Products and a Very Weak Revenue, Here’s What Makes Kite Pharma So Mighty
November 8, 2016
 · 
2 min read
Novartis Unloads Former New York Space for $18 Million, Resold for $30 Million
Business
Watch Out Juno and Kite Pharma: Novartis AG Clearly Not Done With CAR-T
October 25, 2016
 · 
2 min read
Load More
AWARDS
  • 2023 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
December 8, 2025
 · 
19 min read
Press Releases
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
December 8, 2025
 · 
6 min read
Press Releases
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
December 8, 2025
 · 
10 min read
Press Releases
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
November 3, 2025
 · 
19 min read
Press Releases
Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
June 2, 2025
 · 
17 min read
Press Releases
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
May 15, 2025
 · 
19 min read
Press Releases
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
December 10, 2024
 · 
19 min read
Press Releases
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
December 10, 2024
 · 
18 min read
Press Releases
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
December 9, 2024
 · 
19 min read
Biotech Bay
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 9, 2024
 · 
9 min read
Load More